Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age. Final Report: A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine (20vPnC) When Coadministered With Seasonal Inactivated Influenza Vaccine (SIIV) in Adults ≥65 Years of Age.
Category & Conditions: Vaccine-related Conditions
Medicine: PF-06482077
ClinicalTrials.gov Identifier (NCT): NCT04526574
Protocol ID: B7471004
Open Plain Language Summary Result:
Click here